Why is Insmed stock climbing today?

Insmed's stock surged 2.0% in early trading following the U.S. Food and Drug Administration's acceptance of Priority Review for its supplemental New Drug Application (sNDA) for ARIKAYCE, an inhalable amikacin formulation. This approval, anticipated by January 28, 2027, aims to convert ARIKAYCE's accelerated approval from 2018 for refractory MAC lung disease into full approval.

The sNDA is supported by Phase 3b ENCORE study results, which showed significant improvements in culture conversion and respiratory symptoms compared to standard multidrug therapy. Full approval would broaden ARIKAYCE's use to earlier disease stages, including new patients and those with recurrent infections, a market segment currently unaddressed under the accelerated label.

Additionally, Insmed plans to seek Japanese regulatory approval in Q4 2026, broadening international growth potential. Analysts maintain a strong buy rating with average price targets above the current price. The market's positive sentiment, with the Nasdaq composite up 1.0%, S&P 500 up 0.6%, and Dow Jones up 0.9%, further fueled the stock's rise.

Despite being below its 52-week high of $212.75, the stock's gain highlights the resolution of regulatory uncertainty following today's FDA announcement.